ClinicalTrials.gg
CompletedNCT04959019EMemREUpdated Mar 11, 2026

Exercise for Memory Rehabilitation in Epilepsy

An interventional study of Supervised combined endurance and resistance training (CERT) and Delayed supervised combined endurance and resistance training (CERT) in Epilepsy, Generalized and Memory Impairment, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine how effective a 6-week exercise program is for improving memory compared to a no-intervention control group, investigate the brain changes that may be responsible for memory improvements, and determine if the memory benefits and brain changes are retained 6 weeks after completing the exercise intervention in people with Idiopathic generalized epilepsy (IGE).

Read the detailed description

The primary objectives of this randomized controlled trial are to determine in adults with idiopathic generalized epilepsy (IGE) the efficacy of a 6-week supervised and structured exercise program combining endurance and resistance training for memory rehabilitation, investigate a putative mechanisms of action for exercise-related memory benefits, and determine if the memory benefits and brain changes are retained 6 weeks after completing the exercise intervention. Based on the investigators' pilot exercise data in adults with epilepsy, they hypothesize that exercise will significantly improve verbal memory function in the exercise group compared to the no-intervention control group. The investigators also hypothesize that the verbal memory improvements are mediated by the changes in resting state functional connectivity (rsFC) of the hippocampus, a brain region that plays a vital role in memory function. The investigators propose a mediation model in which exercise-induced changes in the hippocampus rsFC is mediating the beneficial effect of exercise on memory function in epilepsy, and will utilize the causal-steps approach in which 4 conditions of statistical significance must be met to determine if mediation is present.

02

Conditions studied

  • Epilepsy, Generalized
  • Memory Impairment

Keywords

  • Epilepsy, Idiopathic Generalized
  • Memory Impairment
  • Magnetic Resonance Imaging
  • Neuroimaging
  • Endurance and Resistance Training
  • Resting State Functional Connectivity
  • Verbal Learning and Memory
03

In context

Epilepsy, Generalized

39 studies on the registry are indexed under Epilepsy, Generalized; 4 are open to participants now.

This study's enrollment of 71 is close to the median of 75 across 25 interventional studies indexed under Epilepsy, Generalized.

Browse Epilepsy, Generalized studies →

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,421 studies on the registry; 277 are open to participants now.

Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • males and females
  • ages 18-65 years old
  • speaks English fluently
  • able to provide written
  • have no to 3-Telsa MRI
  • clinician-confirmed diagnosis of IGE (IGE includes epilepsy syndromes such as juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, and generalized tonic-clonic seizures alone)
  • relatively healthy with no comorbid medical conditions besides epilepsy
  • normal pre-enrollment structural clinical MRI of the brain (if available)
  • having less than the American Heart Association recommendation of physical activity in adults (at least 30 min moderate-intensity aerobic activity at least 5 days/week (150 min total), or at least 25 min vigorous aerobic activity at least 3 days/week (75 min total) and moderate-/high-intensity muscle strengthening activity at least 2 days/week)

Exclusion criteria

Exclusion Criteria:

  • underlying degenerative or metabolic disorders
  • abnormal general or neurological examination
  • abnormal brain MRI
  • recent suicidal ideation in the last 3 months determined based on previous medical history
  • pregnant or positive pregnancy test result on the day of the research session
  • to an MRI scan at 3-Telsa
  • mental handicap (FSIQ\<80 if tested) or history of special education
  • concurrent participation in a different intervention study
  • diseased or enlarged heart or blood vessels determined based on previous medical history
  • high blood pressure that is not controlled by medications
  • meeting the American Heart Association recommendation of physical activity in adults
  • abnormal physical examination in which study physician determines subject should not participate in the exercise intervention
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Immediate Exercise

    immediate participation in 6-week exercise program (intervention)

    Behavioral: Supervised combined endurance and resistance training (CERT)

  • Other
    Delayed Exercise

    6-week delay (no-intervention control) prior to participating in exercise program

    Behavioral: Delayed supervised combined endurance and resistance training (CERT)

Interventions

  • BehavioralSupervised combined endurance and resistance training (CERT)

    Subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.

  • BehavioralDelayed supervised combined endurance and resistance training (CERT)

    After a 6-week delay period (no-exercise control), subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.

06

What researchers measure

Primary outcomes

  1. estimated interaction effect between exercise group and visit for d'

    Repeated measures analysis of variance (rm-ANOVA) will be performed to examine condition-by-time interactions for our primary variable of interest, d', which is the discriminability index for delayed recognition memory on the California Verbal Learning Test - II (CVLT-II). Range is negative infinity to positive infinity for estimated interaction effect.

    Time frame: 6 weeks after baseline

  2. estimated mediation effect of change in left hippocampus resting state functional connectivity (rsFC) in the effect of exercise on change in d'

    Regression tests of mediation for change in left hippocampus rsFC as the mediator variable in the effect of exercise on change in d' (from CVLT-II) will be performed using the causal-steps approach. The four steps in the causal process must be true for mediation to be present. Range is negative infinity to positive infinity for estimated mediation effect.

    Time frame: 6 weeks after baseline

Secondary outcomes

  1. estimated interaction effect between exercise group and visit for Learning score

    Repeated measures analysis of variance (rm-ANOVA) will be performed to examine condition-by-time interactions for our secondary variable of interest, Learning score, which is the total words recalled immediately after the learning trials on the CVLT-II. Range is negative infinity to positive infinity for estimated interaction effect.

    Time frame: 6-weeks after baseline

  2. estimated interaction effect between exercise group and visit for Long Delay Free Recall score

    Repeated measures analysis of variance (rm-ANOVA) will be performed to examine condition-by-time interactions for our secondary variable of interest, Long Delay Free Recall score, which is the total words recalled 30 minutes after the learning trials on the CVLT-II. Range is negative infinity to positive infinity for estimated interaction effect.

    Time frame: 6-weeks after baseline

  3. estimated mediation effect of change in right hippocampus resting state functional connectivity (rsFC) in the effect of exercise on change in d'

    Regression tests of mediation for change in right hippocampus rsFC as the mediator variable in the effect of exercise on change in d' (from CVLT-II) will be performed using the causal-steps approach. The four steps in the causal process must be true for mediation to be present. Range is negative infinity to positive infinity for estimated mediation effect.

    Time frame: 6-weeks after baseline

  4. estimated interaction effect between exercise group and visit for Montreal Cognitive Assessment (MoCA) score

    Repeated measures analysis of variance (rm-ANOVA) will be performed to examine condition-by-time interactions for our secondary variable of interest, MoCA score, which is a measure of general cognitive functioning. Range is negative infinity to positive infinity for estimated interaction effect.

    Time frame: 6-weeks after baseline

  5. estimated interaction effect between exercise group and visit for Short-Form 36 (SF-36) physical component score

    Repeated measures analysis of variance (rm-ANOVA) will be performed to examine condition-by-time interactions for our secondary variable of interest, SF-36 physical component score, which is a quality of life subscale measure for physical health. Range is negative infinity to positive infinity for estimated interaction effect.

    Time frame: 6-weeks after baseline

  6. estimated interaction effect between exercise group and visit for Short-Form 36 (SF-36) mental component score

    Repeated measures analysis of variance (rm-ANOVA) will be performed to examine condition-by-time interactions for our secondary variable of interest, SF-36 mental component score, which is a quality of life subscale measure for mental health. Range is negative infinity to positive infinity for estimated interaction effect.

    Time frame: 6-weeks after baseline

  7. estimated interaction effect between exercise group and visit for Long Delay Cued Recall score

    Repeated measures analysis of variance (rm-ANOVA) will be performed to examine condition-by-time interactions for our secondary variable of interest, Long Delay Cued Recall score, which is the total words recalled after being given a cue when tested 30 minutes after the learning trials on the CVLT-II. Range is negative infinity to positive infinity for estimated interaction effect.

    Time frame: 6 weeks after baseline

  8. estimated interaction effect between exercise group and visit for Short Delay Cued Recall score

    Repeated measures analysis of variance (rm-ANOVA) will be performed to examine condition-by-time interactions for our secondary variable of interest, Short Delay Cued Recall score, which is the total words recalled after being given a cue when tested immediately after the learning trials on the CVLT-II. Range is negative infinity to positive infinity for estimated interaction effect.

    Time frame: 6 weeks after baseline

  9. estimated mediation effect of change in right hippocampus resting state functional connectivity (rsFC) in the effect of exercise on change in Long Delay Cued Recall score

    Regression tests of mediation for change in right hippocampus rsFC as the mediator variable in the effect of exercise on change in Long Delay Cued Recall score (from CVLT-II) will be performed using the causal-steps approach. The four steps in the causal process must be true for mediation to be present. Range is negative infinity to positive infinity for estimated mediation effect.

    Time frame: 6-weeks after baseline

07

Study locations

1 site
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04959019
Responsible party
Jane Allendorfer (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Jul 12, 2021
Start date
Jul 21, 2021
Primary completion
Feb 18, 2026
Completion
Feb 18, 2026
Last update
Mar 11, 2026

Study contacts

Jane B. Allendorfer, Ph.D.
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion